Posted: 2 December
INOVIQ Limited has announced that it has transferred all research, development and manufacturing for EXO-NET to its Melbourne facility.
The company has indicated that this ‘exosome core facility’ will allow INOVIQ to streamline its research and development, expand its capacity to permit large-scale good manufacturing practice production, automate exosome isolation, and develop next-generation products.
The move will also expand INOVIQ’s access to the Australian government’s research and development Tax Incentive scheme (which refunds up to 43.5% of eligible research and development spend).
